PT94030A - PROCESS OF PREPARATION OF ANTIGEN PROTECTIVE AGAINST BORDETELLA INFECTIONS AND TOXIC EFFECTS - Google Patents

PROCESS OF PREPARATION OF ANTIGEN PROTECTIVE AGAINST BORDETELLA INFECTIONS AND TOXIC EFFECTS

Info

Publication number
PT94030A
PT94030A PT94030A PT9403090A PT94030A PT 94030 A PT94030 A PT 94030A PT 94030 A PT94030 A PT 94030A PT 9403090 A PT9403090 A PT 9403090A PT 94030 A PT94030 A PT 94030A
Authority
PT
Portugal
Prior art keywords
preparation
toxic effects
protective against
against bordetella
antigen protective
Prior art date
Application number
PT94030A
Other languages
Portuguese (pt)
Other versions
PT94030B (en
Inventor
Nicole Guiso-Maclouf
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of PT94030A publication Critical patent/PT94030A/en
Publication of PT94030B publication Critical patent/PT94030B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a method of immunizing a mammal against infection by a first Bordetella species. The method comprises administering to the mammal a preparation comprising a portion of the amino acid sequence of mature adenylate cyclase of a second Bordetella species. The invention also relates to vaccine preparations comprising a portion of the amino acid sequence of mature adenylate cyclase from Bordetella species.
PT94030A 1989-05-12 1990-05-14 PROCESS OF PREPARATION OF ANTIGEN PROTECTIVE AGAINST BORDETELLA INFECTIONS AND TOXIC EFFECTS PT94030B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906321A FR2646776B1 (en) 1989-05-12 1989-05-12 USE OF VACCINANT PREPARATIONS BASED ON ADENYL CYCLASE OR OF BACTERIA PRODUCING THEM AS PROTECTIVE ANTIGENS AGAINST THE EFFECTS OF BORDETELLA

Publications (2)

Publication Number Publication Date
PT94030A true PT94030A (en) 1991-01-08
PT94030B PT94030B (en) 1997-07-31

Family

ID=9381646

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94030A PT94030B (en) 1989-05-12 1990-05-14 PROCESS OF PREPARATION OF ANTIGEN PROTECTIVE AGAINST BORDETELLA INFECTIONS AND TOXIC EFFECTS

Country Status (10)

Country Link
US (3) US6214356B1 (en)
EP (1) EP0424518B1 (en)
JP (1) JP3399525B2 (en)
AT (1) ATE115861T1 (en)
CA (1) CA2033085C (en)
DE (1) DE69015314T2 (en)
ES (1) ES2066206T3 (en)
FR (1) FR2646776B1 (en)
PT (1) PT94030B (en)
WO (1) WO1990013312A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (en) 1989-05-12 1994-06-03 Pasteur Institut USE OF VACCINANT PREPARATIONS BASED ON ADENYL CYCLASE OR OF BACTERIA PRODUCING THEM AS PROTECTIVE ANTIGENS AGAINST THE EFFECTS OF BORDETELLA
US6030625A (en) * 1994-12-15 2000-02-29 Institut Pasteur Bordetella pertussis and Bordetella parapertussis strains
FR2728170A1 (en) * 1994-12-15 1996-06-21 Pasteur Institut ANTI-BORDETELLA CELL-LIKE VACCINE
FR2736064B1 (en) 1995-06-30 1997-09-05 Pasteur Institut PROTECTIVE EPITOPES OF ADENYL CYCLASE-HEMOLYSIN (AC-HTY). THEIR APPLICATION TO THE TREATMENT OR PREVENTION OF BORDETELLA INFECTIONS
US7462472B2 (en) * 2001-11-02 2008-12-09 The University Of Chicago Methods and compositions relating to anthrax pathogenesis
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US7521059B2 (en) * 2004-06-14 2009-04-21 Fenwick Bradley W Kennel cough vaccine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237052A (en) 1984-05-12 1993-08-17 Burroughs Wellcome Company Antigenic preparations and isolation of such preparations
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
US4652521A (en) * 1985-03-04 1987-03-24 Regents Of The University Of Minnesota Method for the early diagnosis of bordetella diseases and kit therefor
FR2590483B1 (en) * 1985-11-22 1988-12-09 Pasteur Institut PURIFIED ANTIGENS HAVING VACCINATION PROPERTIES AGAINST B. PERTUSSIS, IN PARTICULAR RECOMBINANT DNA MEANS, AND VACCINE COMPOSITIONS CONTAINING THEM
EP0267998A1 (en) * 1986-11-17 1988-05-25 Institut Pasteur Means for protecting against bordetella infections and toxic processes
FR2606789B1 (en) 1986-11-17 1991-05-31 Pasteur Institut PURIFIED ADENYLATE CYCLASE PREPARATIONS, PROCESS FOR OBTAINING SUCH PREPARATIONS AND THEIR BIOLOGICAL APPLICATIONS
FR2621597B1 (en) * 1987-07-24 1992-07-31 Pasteur Institut METHOD FOR CLONING AND EXPRESSING GENES ENCODING PROTEINS CONSTITUTING ORGANIZED FUNCTIONAL BUILDINGS
EP0338170A1 (en) * 1988-04-19 1989-10-25 Institut Pasteur Immunoprotective antigenic protein against pathogenic bacteria
EP0691348A1 (en) * 1988-04-19 1996-01-10 Institut Pasteur Immunogenic compositions prepared from adenylate cyclase of B. Parapertussis
FR2638169B1 (en) * 1988-10-25 1991-01-11 Pasteur Institut ADENYL CYCLASE DERIVATIVES AND THEIR BIOLOGICAL USES
FR2646776B1 (en) 1989-05-12 1994-06-03 Pasteur Institut USE OF VACCINANT PREPARATIONS BASED ON ADENYL CYCLASE OR OF BACTERIA PRODUCING THEM AS PROTECTIVE ANTIGENS AGAINST THE EFFECTS OF BORDETELLA
EP0425082B1 (en) * 1989-09-04 1995-04-26 Evans Medical Limited Bordetella vaccines
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
ATE263244T1 (en) * 1992-08-18 2004-04-15 Dimminaco Ag BORDETELLA BRONCHISEPTICA VACCINE
US6030625A (en) * 1994-12-15 2000-02-29 Institut Pasteur Bordetella pertussis and Bordetella parapertussis strains
FR2728170A1 (en) * 1994-12-15 1996-06-21 Pasteur Institut ANTI-BORDETELLA CELL-LIKE VACCINE
DK0824358T3 (en) * 1995-05-04 2003-01-27 Aventis Pasteur Acellular pertussis vaccines and methods for their preparation
FR2736064B1 (en) 1995-06-30 1997-09-05 Pasteur Institut PROTECTIVE EPITOPES OF ADENYL CYCLASE-HEMOLYSIN (AC-HTY). THEIR APPLICATION TO THE TREATMENT OR PREVENTION OF BORDETELLA INFECTIONS
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE60133734T2 (en) * 2000-05-25 2009-05-14 Institut Pasteur POLYPEPTIDES THE POLYMORPHISMS CONTAINING BORDERTELLA PERTUSSIS, BORDETELLA PARAPERTUSSIS AND BORDETELLA BRONCHISEPTICA PERTACTIN REPEATED REGIONS, THEIR USE IN DIAGNOSTIC AND IMMUNOGENIC COMPOSITIONS
ES2331348T3 (en) 2000-09-15 2009-12-30 Pasteur Institut PROTEINIC VECTORS FOR THE SUPPLY OF MOLECULES TO THE CELLS THAT EXPRESS CD11B.

Also Published As

Publication number Publication date
US7211263B2 (en) 2007-05-01
US6214356B1 (en) 2001-04-10
DE69015314T2 (en) 1996-11-28
JPH03506044A (en) 1991-12-26
PT94030B (en) 1997-07-31
ES2066206T3 (en) 1995-03-01
WO1990013312A1 (en) 1990-11-15
CA2033085A1 (en) 1990-11-13
US20030224003A1 (en) 2003-12-04
ATE115861T1 (en) 1995-01-15
FR2646776A1 (en) 1990-11-16
EP0424518B1 (en) 1994-12-21
US20020172691A1 (en) 2002-11-21
JP3399525B2 (en) 2003-04-21
EP0424518A1 (en) 1991-05-02
CA2033085C (en) 2003-07-22
DE69015314D1 (en) 1995-02-02
FR2646776B1 (en) 1994-06-03

Similar Documents

Publication Publication Date Title
ATE196605T1 (en) GROUP A STREPTOCOCCAL POLYSACCHARIDES IMMUNOGEN COMPOSITIONS AND METHODS
PL304419A1 (en) Urease based vaccine against heliobacter infections
MX9301706A (en) VACCINE COMPOSITION FOR THE TREATMENT OF HELICOBACTER INFECTION.
ATE430200T1 (en) VACCINE AGAINST THE VIRUS RESPONSIBLE FOR RESPIRATORY AND REPRODUCTIVE DISEASES IN SWINE
UA40597C2 (en) Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
DE69331758D1 (en) Fibrinogen-EDUCATION PROTEIN
ES2100240T3 (en) BACTERIOPHAGUS MODIFIED BY GENETIC ENGINEERING AND VACCINES THAT CONTAIN THEM.
NO950483L (en) Hepatitis A vaccine
PT94030A (en) PROCESS OF PREPARATION OF ANTIGEN PROTECTIVE AGAINST BORDETELLA INFECTIONS AND TOXIC EFFECTS
CA2217522A1 (en) Isolated frpb nucleic acid molecule and vaccine
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
EP0161095A3 (en) Vaccine against urinary infection
PT99923A (en) METHOD FOR PREPARING HIBRID PROTEINS OF PLASMODIUM FALCIPARUM CONTAINING SEQUENCES OF ANTIGENES OF HRPII AND SERP MALARIA AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THESE PROTEINS
Panse et al. Passive immunity in experimental cholera
ATE111485T1 (en) PEPTIDE TREATMENT OF PERSISTENT INFECTIOUS DISEASES.
Puentes et al. Efficacy of Various Non‐Oily Adjuvants in Immunization Against the Aujeszky's Disease (Pseudorabies) Virus
ATE439857T1 (en) LIPOGLYCAN COMPOSITIONS AND METHODS FOR TREATING PARASITIC INFECTIONS
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
NO934547L (en) Oral treatment of Helicobacter infection
MY104932A (en) Immunomodulatory azaspiranes

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19970506

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20120507